Skip to main content
Xbrane Biopharma logo

Xbrane Biopharma — Investor Relations & Filings

Ticker · XBRANE ISIN · SE0007789409 LEI · 5493008DKD05APTKQO39 ST Manufacturing
Open in API
Filings indexed 359 across all filing types
Latest filing 2022-10-18 Capital/Financing Update
Country SE Sweden
Listing ST XBRANE

About Xbrane Biopharma

https://xbrane.com/en/

Xbrane Biopharma is a biotechnology company that specializes in the development of biosimilars—follow-on versions of approved biological drugs. The company's mission is to enhance the accessibility of biological treatments for serious diseases by creating more affordable alternatives. Xbrane utilizes a patented platform technology and efficient manufacturing systems, employing both bacterial and mammalian cells, to achieve lower production costs. Its development pipeline includes several biosimilar candidates, with a key product being a ranibizumab biosimilar.

Recent filings

Filing Released Lang Actions
Xbrane Biopharma offentliggör avsikt att genomföra en riktad nyemission
Capital/Financing Update Classification · 100% confidence The document is a press release from Xbrane Biopharma announcing its intention to conduct a directed share issue (a private placement) to institutional investors. It details the purpose of the capital raise, the bookbuilding process, lock-up agreements, and legal disclaimers regarding the offering. This falls under the category of capital and financing updates.
2022-10-18 Swedish
Xbrane announces intention to carry out a directed share issue
Capital/Financing Update Classification · 100% confidence The document is a press release announcing the company's intention to conduct a 'directed share issue' (a capital raise) via an accelerated book-building process. It details the purpose of the capital, the involvement of financial advisers, and regulatory disclaimers regarding the offering. This fits the definition of a 'Capital/Financing Update' (CAP) as it pertains to fundraising and capital structure changes.
2022-10-18 English
STADA and Xbrane welcome EMA positive opinion for ranibizumab biosimilar candidate Ximluci
Regulatory Filings Classification · 99% confidence The document is a press release dated September 16, 2022, announcing that the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion for the biosimilar candidate Ximluci®. It details the significance of this regulatory step, the product's intended use, and the next steps (referral to the European Commission). It also includes standard 'About Us' sections for both STADA and Xbrane, and contact information. This type of announcement, detailing a specific regulatory milestone or event outcome, fits best under the general 'Regulatory Filings' category (RNS) as it is not a full financial report (10-K, IR), an earnings release (ER), or a specific management/board change (MANG). Although it relates to a product approval process, it is an announcement of a regulatory event, not the final financial results or a formal statutory filing like a 10-K or DEF 14A. Given the options, RNS serves as the most appropriate catch-all for significant, non-financial, non-meeting related regulatory news announcements.
2022-09-16 English
STADA och Xbrane välkomnar EMA:s positiva utlåtande för ranibizumab biosimilarkandidaten Ximluci
Regulatory Filings Classification · 95% confidence The document is a press release dated September 16, 2022, announcing that the European Medicines Agency's (EMA) Committee for Human Medicinal Products (CHMP) has issued a positive opinion for the biosimilar candidate Ximluci®. This is an announcement regarding a significant regulatory milestone (positive opinion leading to potential EU approval) for a pharmaceutical product. It is not a full Annual Report (10-K), an Interim Report (IR), or a formal Earnings Release (ER). Since it is a specific regulatory/scientific update that doesn't fit the other specialized categories (like DIRS, DIV, CAP), it falls best under the general 'Regulatory Filings' (RNS) category, which serves as a broad category for official company announcements that are not otherwise classified. The document length is substantial (7189 chars), so it is the announcement itself, not just a pointer to a report.
2022-09-16 Swedish
Interim / Quarterly Report 2022
Interim / Quarterly Report Classification · 100% confidence The document is a comprehensive financial report for the first half of 2022 (Jan-June), containing detailed financial statements, management commentary (VD-ord), and operational updates. It is not an announcement of a report, but the report itself, and it covers a period shorter than a full fiscal year, fitting the definition of an Interim/Quarterly Report. Q2 2022
2022-07-22 Swedish
Interim / Quarterly Report 2022
Interim / Quarterly Report Classification · 100% confidence The document is a comprehensive financial report for the second quarter and first half of 2022, containing detailed financial statements (Revenue, EBITDA, Net Result, EPS, Cash flow), a CEO's letter, and a detailed product candidate portfolio analysis. It is not an earnings release (which would be a short summary) nor a full annual report (10-K). It fits the definition of an Interim/Quarterly Report (IR) as it provides substantive financial data and analysis for a period shorter than a full fiscal year. Q2 2022
2022-07-22 English

Browse filings by year

8 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.